Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

ACD/Labs Announce MilliporeSigma Partnership at SMASH 2023

ACD/Labs

The collaboration represents MilliporeSigma’s joint steps toward breakthrough innovation to make research and quality control in the lab more efficient and sustainable. The new ChemisTwin™ platform combines ACD/Labs’ industry-leading NMR predictors with Millipore Sigma’s digital reference materials (dRMs). ACD/Labs, an informatics company that develops and commercializes software in support of R&D, today announced a collaboration with MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company and one of the leading manufacturers/distributors of certified reference material world - wide. Through the first release version of its digital reference material (dRM) platform: ChemisTwin™, MilliporeSigma is providing scientists in quality control labs with an automated structure verification tool by NMR. This tool combines ACD/Labs’ industry-leading automated structure verification and prediction capabilities with Millipore Sigma’s expertise in high quality reference materials manufacturing. "With increasing demand for digital solutions in life sciences, we're proud to provide enabling technologies for MilliporeSigma’s digital reference material ChemisTwin™ platform,” said Andrew Anderson, Vice President of Informatics and Innovation Strategy at ACD/Labs. “Our partnership will empower scientists with a digital means for effective and robust structure verification.” “Our purpose is to shape the future of analytical testing, to make research and quality control in laboratories more efficient and sustainable. The launch of the ChemisTwin™ platform is a breakthrough innovation in our journey toward this objective, ultimately impacting life and health with science,” said Coralie Leonard, ChemisTwin™ project lead and Digital Business Model Developer, Analytical Chemistry at MilliporeSigma. "We have chosen to partner with ACD/Labs not only for their strong expertise in NMR spectral prediction and comparison, but also because they share our vision and passion to be a driver of industry change.” About ACD/Labs ACD/Labs is a leading provider of scientific software for R&D. We help customers in >94 countries around the world assemble digitized analytical, structural, and molecular information for effective decision-making, problem solving, and product lifecycle control. Our enterprise technologies enable automation of molecular characterization and facilitate chemically intelligent knowledge management. ACD/Labs provides worldwide sales and support and brings decades of experience and success helping organizations innovate and create efficiencies in their workflows. For more information, please visit www.acdlabs.com. Follow us on Twitter and LinkedIn. About the Life Science business of Merck KGaA, Darmstadt, Germany The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck KGaA, Darmstadt, Germany, generated sales of € 22.2 billion in 66 countries. The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com. Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn. All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service. Contact Details ACD/Labs Sanji Bhal +1 416-368-3435 media@acdlabs.com Allison Matthews ACDLabs@racepointglobal.com Company Website https://www.acdlabs.com/

September 18, 2023 03:00 AM Eastern Daylight Time

News Release

Neural Therapeutics looks to history to solve today’s pharmaceutical problems

Neural Therapeutics Inc.

Neural Therapeutics CEO Ian Campbell joined Steve Darling from Proactive to shed light on the company's fascinating journey into the realm of plant-based active substances. Neural Therapeutics is a pioneering company with a unique focus: the development of over-the-counter dietary supplements and therapeutic medicines with a foundation in psychedelic-based treatments, particularly those derived from mescaline-containing cacti. Campbell explained that Neural Therapeutics has taken significant steps in establishing a supply chain in Peru, specifically for sourcing various species of mescaline-containing cacti, including the San Pedro cactus. To support its research initiatives, the company has diligently pursued and obtained the necessary permits from the National Service for Forest and Wildlife in Peru to collect wild species of cacti. These efforts signify a commitment to harnessing the potential of these plants to develop innovative solutions. Neural Therapeutics is strategically positioned to tap into today's burgeoning Nutraceutical and Pharmaceutical markets. By drawing from the rich traditions of utilizing natural substances, particularly those with a history of indigenous use, the company aims to bridge the past with modern science and healthcare. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 15, 2023 01:19 PM Eastern Daylight Time

Video

News Release

Valeo Pharma hits 7th straight consecutive quarter of revenue growth

Valeo Pharma Inc.

Valeo Pharma CEO Steve Saviuk joined Proactive's Steve Darling to share news regarding the company's strong third-quarter performance. The company has once again shattered its own records, demonstrating remarkable growth in various key areas of its business. In 3Q 2023, the company achieved a milestone with record quarterly revenues reaching an impressive $14.1 million, a 132% increase when compared to the $6.1 million generated in the same period of the previous year. Notably, Valeo Pharma's two flagship products for managing asthma, Enerzair and Atectura, were instrumental in driving this growth, with a 234% increase in sales. Adjusted gross profit soared to $5.1 million, marking a 106% rise from the $2.4 million recorded in 3Q 2022. Enerzair and Atectura have emerged as frontrunners in the Canadian asthma market, gaining prominence as essential therapies. The company said it will focus on sales growth and improved gross margins to put it on the path to profitability, with plans to optimize costs further. Valeo Pharma is optimistic about its future prospects and anticipates sustained growth as it continues to serve a vital role in addressing healthcare needs. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

September 15, 2023 01:03 PM Eastern Daylight Time

Video

News Release

CareRX Corporation new CEO sets course for success

CareRx Corporation

CareRx Corporation's new CEO Puneet Khanna joined Steve Darling from Proactive to discuss his new job as CEO. Khanna assumed the role just three months ago and shared his insights on the company's current position and future direction. Khanna brings over 20 years of experience in the pharmacy and senior care sectors to his leadership role at CareRX. Having previously served as the company's Chief Commercial Officer, he is well-versed in the organization's operations and strategic objectives. During the interview, Khanna discussed CareRX's recent second-quarter financial results, emphasizing the company's achievement of organic quarter-over-quarter revenue and adjusted EBITDA growth, which met expectations. These accomplishments are noteworthy, especially in the context of challenges posed by labor market dynamics in the healthcare sector over the past year. Khanna outlined the company's ongoing focus on implementing a comprehensive technology and operational process optimization program. This initiative is expected to yield cost savings and enhance productivity, aligning with CareRX's commitment to delivering high-quality care while remaining operationally efficient. With Khanna's extensive industry experience and the company's dedication to optimizing its operations, CareRX is well-positioned to continue providing vital services in the senior care and pharmacy sectors. As the new CEO, Khanna's vision for the organization's future is anticipated to drive further growth and success. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 14, 2023 01:18 PM Eastern Daylight Time

Video

Align Surgical Associates Welcomes Reconstructive Plastic Surgeon to Burgeoning Gender-Affirming Healthcare Practice

Align Surgical Associates

The California-based gender-affirming healthcare provider Align Surgical Associates Inc. (Align Surgical) announced today that Breanna Y. Jedrzejewski, M.D., M.P.H., has joined its practice. Align Surgical is one of the few interdisciplinary surgical practices in the United States that exclusively provides comprehensive gender-affirming care. “Breanna is a tremendous addition to Align Surgical’s roster of gender-affirming surgeons,” said Align Surgical founder Dr. Thomas Satterwhite. “She brings a breadth of experience, intelligence and compassion to her work and enables us to offer our patients a wider range of practitioners to choose from.” Breanna Y. Jedrzejewski, M.D., M.P.H, is a reconstructive plastic surgeon, specializing in gender-affirming surgical procedures for the face, body, chest or “top” and genital or “bottom” areas. Dr. Jedrzejewski received her M.D. from Brown University and holds a Master of Public Health in Global Health from Yale University. She completed her residency in integrated plastic surgery at Oregon Health and Science University, where her training included a high volume and full breadth of gender-affirming surgeries. Dr. Jedrzejewski is based at Align Surgical’s San Francisco office, serving patients from California and across the United States. Recently, Dr. Jedrzejewski was lead author on “Regret After Gender-Affirming Surgery: A Multidisciplinary Approach to a Multifaceted Patient Experience,” published in the July 2023 issue of Journal of Plastic and Reconstructive Surgery. In the study’s cohort of 1,989 patients, only 0.3% requested reversal surgery or transitioned back to their sex assigned at birth. This finding of an extremely low rate of regret is below the 1.0% rate found in a 2021 review of 27 studies that examined rates of regret following gender-affirming surgeries. It is also significantly lower than rates of regret reported for other common surgeries, such as total knee replacement ( 10%), hip replacement (3%) and numerous cosmetic procedures such as rhinoplasty (9%), breast augmentation (3%) and liposuction (13%), as reported by Statista. Dr. Jedrzejewski’s research also identified that providing a care environment that “welcomes and normalizes authentic expression of gender identity, affirms surgical goals without judgment, and destigmatizes the role of mental health in the surgical process [is] foundational to mitigating the occurrence of any form of regret.” “I am thrilled to have found a practice that is as committed to providing a respectful and safe environment for patients as it is to advancing the field of gender-affirming healthcare through ongoing research,” said Dr. Jedrzejewski. “From the beginning, it was clear to me that Align Surgical shares my approach to the practice of medicine, which is to engage with each patient as a whole and unique person.” Align Surgical’s Commitment to Research and Surgical Innovations Align Surgical is distinguished among private surgical practices in having a foundational commitment to research and training, which typically only occur at large teaching hospitals. Its surgeons actively initiate and participate in ongoing research with academic and peer organizations, such as Stanford University Medical Center and World Professional Association for Transgender Health ( WPATH ), to improve outcomes and advance the field of gender-affirming healthcare. Align Surgical is an official rotation site for Stanford’s plastic surgery residents as they receive training in gender-affirming care. Align Surgical is also one of the only private interdisciplinary surgical practices in the United States that is 100% focused on gender-affirming surgery. While the majority of its patients reside in California, nearly 30% of Align Surgical’s patient base comes to the practice from 48 other states and outside the U.S. Initial consultations are tailored to every individual, whether they are transgender, nonbinary or gender-diverse. Align Surgical’s roster of plastic surgeons and reconstructive urologists offer the full array of gender-affirming procedures, including facial feminization and masculinization; chest or “top” surgeries such as mastectomy or breast augmentation; body contouring; and many forms of genital or “bottom” surgery, such as phalloplasty, metoidioplasty, vaginoplasty and more. Since founding the practice, the surgeons at Align Surgical have been at the forefront of developments in surgical technique and practices to improve patient outcomes. Whether it is addressing patient-focused needs such as finding a better solution for post-vaginoplasty dilation; questioning existing and pervasive practices such as withholding hormone therapy prior to surgery; or examining access to care by studying what operations surgeons in the U.S. are willing to perform for patients, the surgeons at Align Surgical are always seeking to contribute to the body of scientific knowledge. Their priority is always to improve patient outcomes and deliver the best care possible. “The field of gender-affirming healthcare – and surgery specifically – is one of the great new frontiers of medicine,” added Dr. Satterwhite. “As societal acceptance of transgender identities grows, our ability to expand access and improve outcomes for patients grows along with it. This is why I went into medicine: to deliver life-saving and life-affirming care to those who need it most.” * * * About Align Surgical Associates Align Surgical Associates was founded in 2018 with the mission of providing gender-affirming surgery to the transgender, non-binary and gender-diverse community with excellence, compassion and the belief that all people deserve to experience the freedom of living as their true selves. Align Surgical’s surgeons in San Francisco and Los Angeles provide the full range of facial, body contouring, top and bottom surgeries and share a commitment to advancing innovation and research in their specialty fields. More information at alignsurgical.com. Media, please note: Visual assets, including photos and video, are available. To request an interview with experts from Align Surgical Associates, please contact Andie Davis at 415.766.8355 or Align@landispr.com. ### Contact Details Landis Communications Inc. Andie Davis +1 415-766-8355 Align@landispr.com Company Website https://www.alignsurgical.com/

September 14, 2023 08:31 AM Pacific Daylight Time

Image

50-Provider FQHC Significantly Reduces Patient No-Show Rate by Implementing healow No-Show Prediction AI Model

eClinicalWorks

Total Health Care, Inc., a Federally Qualified Health Center (FQHC) in Baltimore, Maryland, is successfully leveraging the healow ® no-show prediction AI model to improve patient care, reduce missed appointments, and ultimately increase revenue outcomes. Total Health Care provides primary care — including dental, behavioral health, podiatry, pharmacy services, and more — to nearly 30,000 patients throughout Metropolitan Baltimore, many of whom are at or below the 200% poverty line. By identifying which patients are at a higher risk of missing appointments, Total Health Care can proactively reach out to those patients to remind them of or reschedule their appointments. Missed appointments are a significant challenge for healthcare providers, leading to lost revenue and result in negative health outcomes for patients. With the healow no-show prediction AI model, Total Health Care has reported: A significant decrease in the no-show rate of high-risk no-show patients by 34% An additional 309 appointments in 45 days from reduced no-shows “Missed appointments are a significant challenge to overcome. When the pandemic hit, digitization and optimizing systems became a priority for our organization,” said Marceé J. White, MD, FAAP, chief medical officer of Total Health Care. “As an FQHC, the healow no-show prediction AI model helps us streamline the identification and outreach process to patients likely to miss their appointment. It provides us with an opportunity to increase our patient volume, deliver quality care, and improve efficiencies for the staff.” Using AI and machine learning, the healow no-show prediction model can help practices identify patients with a high no-show probability with 90% accuracy. Once patients with a high no-show probability are identified, practices can utilize eClinicalMessenger to manage outreach efforts with voice messages, secure text messages, and email reminders. With healow Open Access ®, practices can publish open, cancelled, and last-minute rescheduled appointment slots on the practice website to avoid revenue loss, acquire new patients, and limit their waitlist. Using healow CHECK-IN ™ and healow Payment Services ™ makes the pre-visit process convenient and efficient, further reducing the rate of no-shows. These contactless solutions allow patients to check in to their appointment and pay their copay from the comfort of home. “We are excited to see Total Health Care implement the healow no-show prediction AI model to improve its overall impact on patient care,” said Girish Navani, CEO and cofounder of eClinicalWorks. “We strive to deliver FQHC’s like Total Health Care the highest quality of care to their patients and community. The introduction of the no-show model will ultimately reduce the cost of healthcare and encourage better patient outcomes." About Total Health Care Total Health Care, Inc. is a Federally Qualified Health Center (FQHC) dedicated to caring for everyone in our community—especially those who are most in need. Total Health Care is one of Maryland’s largest minority-run, nonprofit, tax-exempt community health centers and annually cares for nearly 30,000 patients throughout Metropolitan Baltimore —many at or below the 200% poverty line. For more information, visit www.totalhealthcare.org. About eClinicalWorks eClinicalWorks was founded in 1999 to help digitize paper charts for ambulatory practices. Today, eClinicalWorks leads the nation in innovation with cloud-based solutions for Electronic Health Records and Practice Management. In addition, we help ambulatory practices, specialists, health centers, urgent care facilities, and hospital systems manage their revenue cycle, patient relationships, and Population Health initiatives. More than 150,000 providers and nearly 1 million medical professionals rely upon the power and scalability of the eCW Cloud for flexible clinical documentation, better front-office workflows, and more efficient billing driven by Robotic Process Automation. We combine innovation, leading-edge technology, and a commitment to patient safety to enable practices to grow and thrive amid the challenges of 21st-century healthcare. For more information, visit www.eclinicalworks.com, follow us on Facebook and Twitter, or call (866) 888-6929. About healow healow ® is a comprehensive, EHR-agnostic, cloud-based platform for patients, practices, payers, hospitals, and health systems. healow provides Patient Relationship Management, clinical and payer insights, and state-of-the-art interoperability solutions. The PRISMA health information search engine gathers patient records from other EHRs and helps providers focus on the most clinically relevant information at the point of care. healow’s Population Health Management tools, including Remote Patient Monitoring, provide real-time data to deepen understanding of patient populations. And healow Insights automates the bidirectional exchange of data between health plans and providers to improve scores on quality measures, help control costs, and promote better medical outcomes. Learn more at plus.healow.com. Contact Details eClinicalWorks Bhakti Shah +1 508-330-6935 Bhakti.Shah@eclinicalworks.com Company Website http://www.eclinicalworks.com/

September 14, 2023 10:20 AM Eastern Daylight Time

Jeffrey P. Halperin Joins AmeriLife as Chief Risk and Compliance Officer

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, announced today that Jeffrey P. Halperin has joined the company as its new Chief Risk and Compliance Officer (CRCO). Reporting to AmeriLife’s Chief Legal and Administrative Officer, Nathan Hightower, Halperin will oversee the company’s Compliance Department and lead an enterprise-wide approach to identifying, assessing and mitigating risks that the company may face to ensure that AmeriLife has the proper controls in place to achieve its business objectives. “We’re thrilled to welcome Jeff to AmeriLife and excited to add someone of his caliber to our organization,” said Hightower. “The need for a modern, best-in-class approach to corporate compliance and risk management has never been higher. Under Jeff’s leadership, I’m confident that he’ll continue to build and enhance our services to support the evolving needs of our company and partners.” Halperin comes to AmeriLife from Brighthouse Financial, the spinoff of MetLife’s former Retail Division, where he served as Chief Compliance Officer and Associate General Counsel, since 2017. In this role, he was responsible for managing Brighthouse Financial’s Compliance Department, which was charged with mitigating regulatory risk for the company. He also led the company’s Distribution and Vendor Contracts legal functions, Procurement, and Third-Party Risk Management. Prior to Brighthouse Financial, Halperin worked for nearly 20 years within MetLife’s Corporate Ethics & Compliance Department in a variety of roles, including as MetLife’s Global Money Laundering Prevention Officer; CCO of the MetLife Funds, MetLife Advisers, and MetLife Securities; and Senior Vice President of Compliance for MetLife’s U.S. Businesses. For more than 30 years, Halperin has been an active participant in the industry, serving on various industry committees and speaking at numerous industry conferences on topics related to securities and insurance regulation. Halperin, who will be based at AmeriLife’s Clearwater, Fla., headquarters, is a graduate of the University of Michigan and the University of Connecticut School of Law. “I am very excited to be joining AmeriLife at a time of impressive sales growth,” said Halperin. “I look forward to bringing my metrics-driven, process-oriented approach to the Risk and Compliance functions, so my team can help ensure that AmeriLife achieves its goals in a risk-aware and legally-compliant manner.” ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as an industry leader in developing, marketing and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a national distribution network of over 300,000 agents and financial professionals and more than 120 marketing organizations and insurance agencies. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

September 14, 2023 09:00 AM Eastern Daylight Time

The Cultivated B Initiated Pre-Submission Process towards EFSA Certification for Cultivated Sausage

The Cultivated B

The Cultivated B (TCB) began discussions with the European Food Safety Authority (EFSA) and officially entered the pre-submission proces s for novel food approval of a novel or non-farmed sausage product. Subsequent to the official submission, TCB will emerge as world’s first biotech company to apply for EFSA certification for cultivated meat. This is a pivotal first step in the evolution of the cultivated meat market and establishes a viable path towards large-scale commercial production. “EFSA's Novel Food regulatory approvals process is among the most robust in the world, including a thorough and evidence-based assessment of food safety and nutritional value. For cultivated meat to become available in Europe, where this food was born, would mark a paradigm shift for the sector,” said Seth Roberts, policy manager at the Good Food Institute Europe. One of the most significant challenges in the cultivated meat sector is achieving production at the enormous volumes required by the food producer industry. In addition, food safety concerns and regulatory compliance further hinder cultivated meat from reaching consumers. TCB's early engagement with EFSA is a testament to knocking down these barriers, propelling the industry to democratize cultivated meat for the masses without compromising on quality or sustainability. "This is more than just a certification process; it’s a testament to our advanced, industrial-scale cellular agriculture technology and also a reflection of our unwavering commitment to usher in a new era of food production—one where health, taste, ethics and sustainability converge seamlessly,” said TCB CEO Dr. Hamid Noori. “The European cultivated meat sector has vast potential and considerable opportunity for growth. As this market gains prominence, our objective is to ensure consistent access to high-quality, sustainable meat for everyone. Attaining EFSA certification is a significant step in this direction.” The cell-based sausage product for which TCB seeks EFSA certification is similar to boiled sausages used in hot dogs and has been developed in close collaboration with TCB sister company The Family Butchers. It is a hybrid sausage product composed of vegan ingredients, including significant amounts of cultivated meat. Leveraging the combined expertise of both entities ensures that consumers will experience the familiar, delectable taste they love, all while benefiting from a sustainable and ethically produced product. EFSA certification is governed by a strict regulatory framework which emphasizes food safety standards. Achieving certification by EFSA for TCB’s cultivated sausage will indicate the safety of its cultivated meat products as measured by the highest European standards. It also charts the course and lays the groundwork for regulatory approvals worldwide. This strategic roadmap underscores the company’s determination to lead in the global cultivated meat industry, giving hundreds of startups in this space a path toward viable and scalable commercialization, setting new standards in food safety, innovation, and accessibility. About The Cultivated B (TCB) The Cultivated B’s multinational team of scientists develops and applies breakthrough technologies in cellular agriculture, precision fermentation and advanced bioreactor technology to enable scalable commercialization of the cellular-agriculture industry. TCB serves startups, corporations and academic research institutions within the food, pharma, cosmetics and personal care industries. With its pioneering engineering and production capabilities, TCB enables other companies to produce alternative proteins, such as cultivated meat, at industrial scale. The company’s fundamental commitment to minimizing the natural resources used paves the way toward a sustainable future, locally, regionally and globally. TCB’s research and development team is based in Germany, with manufacturing and an innovation hub based in Canada’s Toronto region. For more information, visit https://www.thecultivatedb.com and follow the company on LinkedIn. Contact Details Rainier Communications Jenna Beaucage +1 508-340-6851 tcb@rainerco.com Company Website https://www.thecultivatedb.com

September 14, 2023 08:06 AM Eastern Daylight Time

MVision AI Is Selected To Provide Its Contour+ Solution By The Republic Of Ireland’s Health Service Executive (HSE) For Its First Installation In The Country

MVision AI

MVision AI is experiencing ongoing and rapid growth within the health service sector globally. The company is delighted to announce that we have successfully been awarded the tender from the Republic of Ireland’s Health Service Executive (HSE) for the installation of our Contour+ auto contouring solution at Cork University Hospital. "MVision AI are truly delighted to have been selected as the preferred supplier of an AI auto contouring system to Cork University Hospital. This will be the first deployment of our Guideline Based Contour+ solution via our Cloud service within this country," says Stewart Pegrum, MVision AI's Vice President of Global Sales. The procurement was undertaken via a national EU tender process, which was published on 3rd February 2023 Each tender applicant was evaluated on Qualitative Selection Criteria including; Economic and Financial Standing, Technical and Professional Ability and Quality Assurance Standards. Tenders that achieve the minimum requirements set out in the Qualitative Selection Criteria were then evaluated to determine which presented the most economically advantageous tender using the award criteria below: Project Management & Installation (5%) Primary Requirements (5%) Functional Requirements (10%) Clinical Requirements (25%) ICT Technical Requirements (10%) Service & Support (5%) Training & Documentation (5%) Sustainability (5%) Cost (30%) As part of the clinical requirements sample delineations for a selection of structures were requested for evaluation purposes from the Tenderers. These were reviewed by the tender panel that was made up of Medical Physicists, Radiation Oncologists, Radiation therapists and HSE procurement representatives. " We recently started SABR Lung treatments and expect to introduce SABR Liver and SRS treatments in the near future. We hope MVision will help us to standardize contouring in line with best practice guidelines and reduce the time spent delineating patient datasets by approximately 50%, " says Mr. Michael Roche, Principal Physicist, Medical Physics Department in Cork University Hospital. MVision AI's interests in the UK and Ireland are represented by our longstanding distributor, Xiel, which specializes in providing solutions for Nuclear Medicine, Radiotherapy, and Diagnostic Radiology. "We are delighted that CUH have selected MVision AI as their solution for auto contouring, this was a very stringent process with much interaction and this award demonstrates the robust capabilities of Contour +", says Phil Neale, Xiel's Key Account Consultant in Radiotherapy Physics. About MVision AI MVision AI is an innovative software service provider for radiotherapy treatment planning. Our AI-powered automatic segmentation tool, Contour+, helps to standardize contouring and automate segmentation to streamline the radiotherapy treatment planning workflow. MVision AI is the AI-powered radiotherapy planning solution for treating cancer; MVision AI uses artificial intelligence to automate cancer treatment planning with its unique guideline-based AI contouring - Contour+; MVision AI announced the new guideline-based automatic segmentation service Contour+ release version 1.2.4 [1]; MVision AI's Contour+ has been officially recommended by NICE (National Institute for Health and Care Excellence) for use within the NHS, alongside several other AI auto-contouring tools[2]; MVision AI process a staggering 2750 scans per month, translating to nearly a quarter of all radiotherapy patients in the UK benefiting from Contour+; The next-generation technology speeds up the entire cancer treatment process, significantly reducing treatment planning time from weeks to days; According to information from the Irish Cancer Society, cancer is the leading cause of death in Ireland: an estimated 44,000 people in Ireland are diagnosed with cancer each year [3]; The scalable platform enables the improvement of cancer treatments worldwide. Contour+ has already been used in treating over 170,000 cancer patients in 16 countries. MVision.ai - Press Release: MVision AI launches Contour+ auto-contouring to facilitate standardization and shorten time to treatment for cancer radiotherapy MVision.ai - Exciting News: AI Auto-Contouring Recommended by NICE for Radiotherapy in the NHS! Irish Cancer Society - Cancer statistics MVision.ai MVision AI Linkedin page MVision AI Media Kit Interview requests: Alena Kruhlova alena.kruhlova@mvision.ai About Cork University Hospital (CUH) Currently Cork University Hospital (CUH) treats c.2000 patients annually. At present, the majority of volume delineation is a time-consuming process and is manually performed by CUH's 7 Consultant Radiation Oncologists who may be assisted at times by other staff members including Dosimetrists or Radiation Therapists. A new radiotherapy facility was opened in 2019. CUH.hse.ie Cork University Hospitals Linkedin Group About Xiel. Xiel is a specialist distributor of medical technologies in the UK and Ireland. We work with global leading solution providers; therefore, continuously improving efficiency and quality for our customers. Our partners research and develop highly specific products for what is often a small world market. The expertise of Xiel lies in our deep understanding of the structure and organisation of radiotherapy departments in the UK and Ireland, for us to advise on the best solutions possible. Xiel. Exceptional Products. Extraordinary Service. Everyday. Xiel.co.uk Xiel Linkedin page Contact Details MVision AI Alena Kruhlova alena.kruhlova@mvision.ai Company Website https://www.mvision.ai/

September 14, 2023 07:17 AM Eastern Daylight Time

Image

1 ... 92 93 94 95 96 ... 303